Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04591431 |
TitleThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | 阶段
第二阶段
|
Date Added 2020-10-19 |
地点
意大利
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib |
标签
MSS/ MMRp
|
| NCT ID NCT04009681 |
Title评估THOR-707对晚期或转移性实体瘤成人受试者安全性和治疗活性的研究 | 阶段
第 1 阶段
|
Date Added 2019-07-05 |
地点
Arizona, United States
Colorado, United States Florida, United States Tennessee, United States Texas, United States 阿根廷 澳大利亚 智利 新加坡 西班牙 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
anti-EGFR antibody, Checkpoint inhibitor, THOR-707 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02215889 |
Title肝脏部分 2/3 移植研究 | 阶段
第 1 阶段
|
Date Added 2014-08-13 |
地点
挪威
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04130854 |
TitleINNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | 阶段
第二阶段
|
Date Added 2019-10-18 |
地点
Arizona, United States
North Carolina, United States Oregon, United States Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days |
标签
MSS/ MMRp
|
| NCT ID NCT03921684 |
Title直肠癌患者化疗后使用 Nivolumab 和 FOLFOX 的试验 | 阶段
第二阶段
|
Date Added 2019-04-19 |
地点
以色列
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
capecitabine, mFOLFOX6, Nivolumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03475004 |
TitleStudy of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | 阶段
第二阶段
|
Date Added 2018-03-23 |
地点
Colorado, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Bevacizumab, and Binimetinib |
标签
MSS/ MMRp
|
| NCT ID NCT04940546 |
TitleNeoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients | 阶段
Phase 1, Phase 2
|
Date Added 2021-06-25 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, capecitabine, oxaliplatin, Sintilimab |
标签
MSS/ MMRp
|
| NCT ID NCT03290937 |
TitleUtomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2017-09-25 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, Irinotecan Hydrochloride, Utomilumab |
标签
MSS/ MMRp
|
| NCT ID NCT03388190 |
TitleMETIMMOX: Colorectal Cancer METastasis – Shaping Anti-tumor IMMunity by OXaliplatin | 阶段
第二阶段
|
Date Added 2018-01-02 |
地点
挪威
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
FLOX, Nivolumab, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT04535024 |
TitleThe Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2020-09-01 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Sintilimab |
标签
MSS/ MMRp
|
